Phase II trial of CEQ 508 for the prevention of colorectal cancer in patients with familial adenomatous polyposis.

Trial Profile

Phase II trial of CEQ 508 for the prevention of colorectal cancer in patients with familial adenomatous polyposis.

Planning
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2012

At a glance

  • Drugs CEQ 508 (Primary)
  • Indications Colorectal cancer; Familial adenomatous polyposis
  • Focus Therapeutic Use
  • Sponsors Cequent Pharmaceuticals
  • Most Recent Events

    • 06 Jan 2012 Marina Biotech receives $US5 million in funds, which will in part aid in financing this trial, as reported in a company media release.
    • 16 Apr 2010 Cequent expects to initiate this trial in 2011, according to a company media release.
    • 16 Apr 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top